ClinicalTrials.gg
CompletedNCT06868264Updated Oct 29, 2026

C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV

A Phase 3 interventional study of Bemnifosbuvir-Ruzasvir (BEM/RZR) and Sofosbuvir-Velpatasvir (SOF/VEL) in HEPATITIS C VIRUS CHRONIC INFECTION, sponsored by Atea Pharmaceuticals, Inc.. Completed at 105 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Atea Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

How we know

Updated Oct 29, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
940
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 725 studies in Hepatitis C with a site in United States — 29 open to participants now, 37 under way, 1 of them phase 3. Hepatitis C · United States.

Enrollment
22nd of 594
940 · median 60
Started
2025
with 5 others
Phase 3
87 of 725
none open now
Registered
717th of 725
by date

Among the 725 studies in Hepatitis C with a site in United States, this one is the 22nd largest by enrollment of the 594 interventional ones that give a count, is one of 6 that started in 2025, is one of 87 in phase 3, and was the 717th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

29 of the 725 studies in Hepatitis C with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 725 studies in Hepatitis C with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.

03

Conditions studied

  • HEPATITIS C VIRUS CHRONIC INFECTION
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Use of adequate for females of
  • Must be direct-acting antiviral (DAA)-treatment-naïve (never exposed to an approved or experimental DAA for )
  • Documented medical history compatible with chronic HCV
  • Either no liver cirrhosis or with compensated liver cirrhosis
  • If -1-positive, must meet the following 2 criteria:

    1. Antiretroviral (ARV) regimen for >8 weeks prior to screening visit, with >200 cells/mm3 and plasma HIV-1 RNA \<LLOQ
    2. Suitable ARV treatment and not taking any medications

Key Exclusion Criteria:

  • Pregnant or breastfeeding
  • Co-infected with virus
  • Abuse of alcohol and/or illicit drug use that could interfere with adherence to study requirements as judged by the investigator
  • Requirement of any prohibited medications
  • Use of other drugs within 30 days of dosing
  • History or signs of decompensated liver disease (decompensated cirrhosis)
  • History of hepatocellular carcinoma (HCC)
  • Any other medical condition that, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
940 participants (actual)

Study arms

  • Experimental
    Bemnifosbuvir-Ruzasvir (BEM/RZR)

    Drug: Bemnifosbuvir-Ruzasvir (BEM/RZR)

  • Active comparator
    Sofosbuvir-Velpatasvir (SOF/VEL)

    Drug: Sofosbuvir-Velpatasvir (SOF/VEL)

Interventions

  • DrugBemnifosbuvir-Ruzasvir (BEM/RZR)

    BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis)

  • DrugSofosbuvir-Velpatasvir (SOF/VEL)

    SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks

06

What researchers measure

Primary outcomes

  1. Proportion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at study week 24.

    Time frame: Day 1 through Week 24

Secondary outcomes

  1. Proportion of subjects achieving HCV RNA < LLOQ 12 weeks after the last dose of study drugs.

    Time frame: Day 1 through 12 weeks after the end of treatment

  2. Proportion of subjects experiencing virologic failure.

    Time frame: Day 1 through Week 24

07

Study locations

105 sites
  • Atea Study Site
    Birmingham, Alabama 35215, United States
  • Atea Study Site
    Dothan, Alabama 36301, United States
  • Atea Study Site
    Chandler, Arizona 85225, United States
  • Atea Study Site
    Flagstaff, Arizona 86001, United States
  • Atea Study Site
    Mesa, Arizona 85210, United States
  • Atea Study Site
    Phoenix, Arizona 85006, United States
  • Atea Study Site
    Phoenix, Arizona 85015, United States
  • Atea Study Site
    Tucson, Arizona 85745, United States
  • Atea Study Site
    Little Rock, Arkansas 72204, United States
  • Atea Study Site
    Bakersfield, California 93301, United States
  • Atea Study Site
    Coronado, California 92118, United States
  • Atea Study Site
    Escondido, California 92025, United States
  • Atea Study Site
    Fresno, California 93711, United States
  • Atea Study Site
    Long Beach, California 98015, United States
  • Atea Study Site
    Los Angeles, California 90048, United States
  • Atea Study Site
    Los Angeles, California 90067, United States
  • Atea Study Site
    Orange, California 92868, United States
  • Atea Study Site
    Pasadena, California 91105, United States
  • Atea Study Site
    Sacramento, California 95817, United States
  • Atea Study Site
    Torrance, California 90502, United States
  • Atea Study Site
    Valencia, California 91355, United States
  • Atea Study Site
    Colorado Springs, Colorado 80907, United States
  • Atea Study Site
    Washington D.C., District of Columbia 20017, United States
  • Atea Study Site
    Washington D.C., District of Columbia 20037, United States
  • Atea Study Site
    Coral Gables, Florida 33134, United States
  • Atea Study Site
    DeLand, Florida 32720, United States
  • Atea Study Site
    Fort Lauderdale, Florida 33308, United States
  • Atea Study Site
    Ft. Pierce, Florida 34982, United States
  • Atea Study Site
    Gainesville, Florida 32610, United States
  • Atea Study Site
    Inverness, Florida 34452, United States
  • Atea Study Site
    Jupiter, Florida 33458, United States
  • Atea Study Site
    Lauderdale Lakes, Florida 33313, United States
  • Atea Study Site
    Maitland, Florida 32751, United States
  • Atea Study Site
    Miami, Florida 33125, United States
  • Atea Study Site
    Miami Lakes, Florida 33014, United States
  • Atea Study Site
    Orlando, Florida 32803, United States
  • Atea Study Site
    Pembroke Pines, Florida 33024, United States
  • Atea Study Site
    Sarasota, Florida 34237, United States
  • Atea Study Site
    West Palm Beach, Florida 33407, United States
  • Atea Study Site
    Macon, Georgia 31201, United States
  • Atea Study Site
    Marietta, Georgia 30060, United States
  • Atea Study Site
    Chicago, Illinois 60613, United States
  • Atea Study Site
    New Albany, Indiana 47150, United States
  • Atea Study Site
    Fairway, Kansas 66205, United States
  • Atea Study Site
    Topeka, Kansas 66606, United States
  • Atea Study Site
    Louisville, Kentucky 40218, United States
  • Atea Study Site
    New Iberia, Louisiana 70560, United States
  • Atea Study Site
    New Orleans, Louisiana 70112, United States
  • Atea Study Site
    Baltimore, Maryland 21201, United States
  • Atea Study Site
    Baltimore, Maryland 21287, United States
  • Atea Study Site
    Boston, Massachusetts 02114, United States
  • Atea Study Site
    Boston, Massachusetts 02118, United States
  • Atea Study Site
    Springfield, Massachusetts 01105, United States
  • Atea Study Site
    Worcester, Massachusetts 01655, United States
  • Atea Study Site
    Detroit, Michigan 48201, United States
  • Atea Study Site
    Grosse Pointe Woods, Michigan 48236, United States
  • Atea Study Site
    Novi, Michigan 48377, United States
  • Atea Study Site
    Wyoming, Michigan 49519, United States
  • Atea Study Site
    Tupelo, Mississippi 38801, United States
  • Atea Study Site
    Camden, New Jersey 08103, United States
  • Atea Study Site
    Hackensack, New Jersey 07601, United States
  • Atea Study Site
    Hillsborough, New Jersey 08844, United States
  • Atea Study Site
    Newark, New Jersey 07102, United States
  • Atea Study Site
    Newark, New Jersey 07103, United States
  • Atea Study Site
    Brooklyn, New York 11215, United States
  • Atea Study Site
    New York, New York 10016, United States
  • Atea Study Site
    Yonkers, New York 10701, United States
  • Atea Study Site
    Asheville, North Carolina 28801, United States
  • Atea Study Site
    Charlotte, North Carolina 28204, United States
  • Atea Study Site
    Fayetteville, North Carolina 28304, United States
  • Atea Study Site
    Beavercreek, Ohio 45440, United States
  • Atea Study Site
    Cincinnati, Ohio 45267, United States
  • Atea Study Site
    Tulsa, Oklahoma 74104, United States
  • Atea Study Site
    Allentown, Pennsylvania 18103, United States
  • Atea Study Site
    DuBois, Pennsylvania 15801, United States
  • Atea Study Site
    Philadelphia, Pennsylvania 19104, United States
  • Atea Study Site
    Philadelphia, Pennsylvania 19107, United States
  • Atea Study Site
    Charleston, South Carolina 29425, United States
  • Atea Study Site
    Chattanooga, Tennessee 37421, United States
  • Atea Study Site
    Cordova, Tennessee 38018, United States
  • Atea Study Site
    Jackson, Tennessee 38301, United States
  • Atea Study Site
    Arlington, Texas 76012, United States
  • Atea Study Site
    Dallas, Texas 75203, United States
  • Atea Study Site
    Dallas, Texas 75242, United States
  • Atea Study Site
    Denison, Texas 75020, United States
  • Atea Study Site
    Houston, Texas 77030, United States
  • Atea Study Site
    Plano, Texas 75093, United States
  • Atea Study Site
    San Antonio, Texas 78215, United States
  • Atea Study Site
    Temple, Texas 76508, United States
  • Atea Study Site
    Waco, Texas 76710, United States
  • Atea Study Site
    Ogden, Utah 84405, United States
  • Atea Study Site
    Chesapeake, Virginia 23320, United States
  • Atea Study Site
    Norfolk, Virginia 23502, United States
  • Atea Study Site
    Richmond, Virginia 23226, United States
  • Atea Study Site
    Richmond, Virginia 23298, United States
  • Atea Study Site
    Seattle, Washington 98101, United States
  • Atea Study Site
    Vancouver, British Columbia V6Z 2C7, Canada
  • Atea Study Site
    Moncton, New Brunswick E1C6Z8, Canada
  • Atea Study Site
    St. John's, Newfoundland and Labrador A1B3V6, Canada
  • Atea Study Site
    Brampton, Ontario L6R 3J7, Canada

Showing the first 100 of 105 sites across 2 countries. Choose a country and city above to see the rest.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Jun 2026, 14 months.

Of 68 industry-sponsored phase 3 interventional studies under Hepatitis C, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 18. This study's 14 months is close to that.

Counting every sponsor, half of 90 studies reached it within 14 months; a quarter within 10 and three quarters within 22.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Sep 2026 → Jun 2026 and completion Dec 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2025
First posted
Mar 10, 2025
StartActual
Apr 7, 2025
Primary completionActual
Jun 18, 2026was Sep 2026
CompletionActual
Sep 9, 2026was Dec 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 29, 2026
Primary completion
Sep 2026→Jun 18, 2026 (actual)
Oct 29, 2026
Study completion
Dec 2026→Sep 9, 2026 (actual)
Oct 29, 2026
Enrollment
880 (estimated)→940 (actual)
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Active, not recruiting→Completed
    Primary completion Sep 2026→Jun 18, 2026 (now actual)
    Study completion Dec 2026→Sep 9, 2026 (now actual)
    Enrollment 880 (estimated)→940 (actual)
    + 1 other change: site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06868264
Responsible party
Sponsor
First posted
Mar 10, 2025
Start date
Apr 7, 2025
Primary completion
Jun 18, 2026
Completion
Sep 9, 2026
Last update
Oct 29, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion